Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2012
07/17/2012US8221793 Chemoembolisation
07/17/2012US8221788 Pharmaceutical compositions containing rosuvastatin calcium
07/17/2012US8221786 Pharmaceutical formulations containing an SGLT2 inhibitor
07/17/2012US8221785 Transdermal hormone delivery system: compositions and methods
07/17/2012US8221784 Transdermal hormone delivery system: compositions and methods
07/17/2012US8221783 Medical devices with triggerable bioadhesive material
07/17/2012US8221779 Compositions and methods for the delivery of poorly water soluble drugs and methods of treatment
07/17/2012US8221775 Pyrrolin-2-ylamino compounds for combating animal pests
07/17/2012US8221771 Formulations containing an immune response modifier
07/17/2012US8221768 Chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence
07/17/2012US8221758 Anti-midkine antibody for preventing post-laparotomy adhesions
07/17/2012US8221737 Hepatitis C virus inhibitors
07/17/2012US8221736 Semiochemical
07/17/2012US8221735 Embolic compositions
07/17/2012US8221733 Acyclic or carbocyclic amines as antiseptics for bathroom fixtures
07/17/2012US8221729 Use of aminophenylbenzotriazole derivatives for protecting human and animal skin and hair from the harmful effects of UV radiation and cosmetic compositions thereof
07/17/2012US8221046 Compositions containing amines and use thereof
07/17/2012CA2763705A1 Hyaluronic acid based mucoadhesive therapeutic composition for the prevention and treatment of epithelial and mucosal lesions of the human body
07/17/2012CA2706264C Propofol transparent anesthetic solution, with low venous irritation threshold
07/17/2012CA2700319C Carbonates for use in the preparation of derivatives of dioxan-2-alkyl carbamates
07/17/2012CA2685674C Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
07/17/2012CA2680853C 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
07/17/2012CA2679973C Orally bioavailable prodrugs of (+)-3-hydroxymorphinan for parkinson's disease prevention or treatment
07/17/2012CA2674436C Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
07/17/2012CA2640483C Laser energy calibration based on optical measurement
07/17/2012CA2637658C Aurora kinase modulators and method of use
07/17/2012CA2559683C Use of rotigotine for treating and preventing parkinson's plus syndrome
07/17/2012CA2559250C X-ray visible drug delivery device
07/17/2012CA2542049C Finely particulate composite containing carbon compound encapsulated therein
07/17/2012CA2540235C Pharmaceutical use of a composition containing fenofibrate
07/17/2012CA2535313C Hiv replication inhibiting purine derivatives
07/17/2012CA2525764C N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
07/17/2012CA2524798C Compositions for controlling parasites on animals
07/17/2012CA2524568C Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof
07/17/2012CA2523672C Compositions for enhancing transport of molecules into cells
07/17/2012CA2522888C Smooth muscle spasmolytic agents
07/17/2012CA2522561C Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
07/17/2012CA2518676C Use of diazoxide in the treatment of ischemia retinae
07/17/2012CA2517372C Pharmaceutical composition of alendronic acid, salts or esters thereof, and a process for its preparation
07/17/2012CA2502437C Method and composition containing latanoprost for treating ocular hypertension and glaucoma
07/17/2012CA2501842C Glucose-based compounds with affinity to p-selectin
07/17/2012CA2497838C Pharmaceutical application of 15- or 16- substituted testosterone analogues
07/17/2012CA2496699C Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
07/17/2012CA2492964C Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
07/17/2012CA2492659C 6-(3-pyridyl-methylamino)purine derivatives and their use as antiproliferative agents
07/17/2012CA2488373C N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris
07/17/2012CA2488366C Biofunctional cpg or oligo-/polynucleotide and toxin or enterotoxin containing composition
07/17/2012CA2482002C Curcumin analogues and uses thereof
07/17/2012CA2477217C Topical dapsone for the treatment of acne
07/17/2012CA2469187C Cis-2,4,5-triphenyl-imidazolines and their use in the treatment of tumors
07/17/2012CA2468796C Biphenylmethyl-thiazolidinediones and analogues and their use as ppar-gamma activators
07/17/2012CA2462455C Development of a preventive vaccine for filovirus infection in primates
07/17/2012CA2451704C Fortified rice bran food product and method for promoting cardiovascular health
07/17/2012CA2451028C Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
07/17/2012CA2448265C Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents
07/17/2012CA2418984C Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof
07/17/2012CA2391392C Methods for screening candidate drugs that disrupt mif and jab1 interaction, mif and jab1 complex, antibodies and uses thereof
07/17/2012CA2334342C Epothilone derivatives and their synthesis and use
07/17/2012CA2266325C A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
07/17/2012CA2259709C Anti-microbial composition
07/12/2012WO2012094638A1 Melanin modification compositions and methods of use
07/12/2012WO2012094636A2 Chemosensory receptor ligand-based therapies
07/12/2012WO2012094618A1 Combination steroid and glucocorticoid receptor antagonist therapy
07/12/2012WO2012094615A2 Use of cav3.1 selective t-type calcium channel antagonists
07/12/2012WO2012094612A1 Method of treating essential tremor
07/12/2012WO2012094600A1 Methods for treating lysosomal storage diseases using l-type ca2+ channel blockers with a 1,4 dihydropyridine structure and inhibitors of er-associated degradation
07/12/2012WO2012094598A2 Pharmaceutical compositions of iron for oral administration
07/12/2012WO2012094515A1 Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer
07/12/2012WO2012094462A2 Heterocyclic compounds for the inhibition of pask
07/12/2012WO2012094451A1 Novel ureas for the treatment and prevention of cancer
07/12/2012WO2012094437A2 Nicotinic receptor non-competitive antagonists
07/12/2012WO2012094313A1 Pyrazole derivatives as erk inhibitors
07/12/2012WO2012094304A1 Nanotubes as carriers of nucleic acids into cells
07/12/2012WO2012094302A2 Drug delivery using fine fiber encapsulation
07/12/2012WO2012094293A1 Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
07/12/2012WO2012094283A2 Bepotastine compositions
07/12/2012WO2012094248A1 O-(substituted benzyl) phosphoramidate compounds and therapeutic use
07/12/2012WO2012094115A1 Compositions and methods for inhibiting expression of flt3 genes
07/12/2012WO2012094081A2 System and method for identifying and applying peripheral treatment mechanisms for disease
07/12/2012WO2012094033A1 Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
07/12/2012WO2012094030A1 Anti-cancer regimen
07/12/2012WO2012094010A1 Compositions and methods of aloe polysaccharides
07/12/2012WO2012094009A2 Methods of reducing surgical site infection
07/12/2012WO2012093979A1 Water-soluble dosage forms comprising ibandronate
07/12/2012WO2012093978A1 Effervescent bisphosphonate formulations
07/12/2012WO2012093977A1 Water soluble pharmaceutical formulations comprising ibandronate and an inorganic salt for use in treatment of bone diseases
07/12/2012WO2012093976A1 A composition comprising ibandronate at least 50 % of a filling agent and a sweetener
07/12/2012WO2012093975A1 Water soluble formulations comprising ibandronate sodium with a water content less than 11 % by weight
07/12/2012WO2012093974A1 Improved bisphosphonate formulations
07/12/2012WO2012093973A2 Stable acarbose formulations
07/12/2012WO2012093972A1 Water soluble dosage forms
07/12/2012WO2012093971A2 Effervescent compositions comprising amlodipine
07/12/2012WO2012093859A2 Antifungal composition including polycyclic peptide compound and method for producing same
07/12/2012WO2012093855A2 Novel flavi mycin compound, antifungal composition including same, and method for producing same
07/12/2012WO2012093809A2 New bicyclic compound for modulating g protein-coupled receptors
07/12/2012WO2012093787A2 Composition for activating gabaa benzodiazepine receptor and composition for anxiety alleviation, convulsion reduction, sedation and sleep induction and improvement containing phloroglucinol, phlorotannin or brown algae extract
07/12/2012WO2012093753A1 Artificial saliva comprising hyaluronic acid
07/12/2012WO2012093741A1 Leukaemia-treatment pharmaceutical composition
07/12/2012WO2012093708A1 Novel bicyclic compound or salt thereof
07/12/2012WO2012093707A1 Novel indole or indazole derivative or salt thereof
1 ... 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 ... 7860